Drugs / Pneumococcal 20-valent Conjugate Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05417165 | Sep 2023 → Oct 2026 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Seema Bhat | Recruiting | No outcome recorded |
| Phase 2 | NCT05183854 | Jan 2022 → Mar 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | University of Utah | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pneumococcal 20-valent Conjugate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05183854 ↗ |
| Modality | Vaccine | “PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease.” NCT05183854 ↗ |
| Route | Intramuscular | “Given IM” NCT05417165 ↗ |